Q-omics provides the consensus-scored LINC02570 profile across patient tissues and cancer cell-line models. LINC02570 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02570 is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, LINC02570 RNA expression shows 11,649 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUAD, and TGCT as cancer lineages where LINC02570 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02570 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02570 survival associations across molecular data types. LINC02570 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02570 RNA expression–survival associations across cancer types. High LINC02570 expression shows unfavorable associations in KIRC, UVM and KIRP, but favorable associations in MESO, CESC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02570 RNA expression.
This table summarizes LINC02570 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02570. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02570 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KICH, KIRC, CHOL and HNSC. The LUAD box plot shows higher LINC02570 RNA expression in normal versus tumor tissue (log2 FC = −1.297, t-test p < 0.001).
This table shows molecular features associated with LINC02570 in patient tissues and cancer cell lines. In patient samples, LINC02570 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
